Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

Orlova, K.V.; Ledin, E.V.; Zhukova, N.V.; Orlova, R.V.; Karabina, E.V.; Volkonskiy, M.V.; Stroyakovskiy, D.L.; Yurchenkov, A.N.; Protsenko, S.A.; Novik, A.V.; Vorotilina, L.V.; Moiseenko, F.V.; Chang, V.L.; Kazmin, A.I.; Tkachenko, S.A.; Gamaunov, S.V.; Naskhletashvili, D.R.; Samoylenko, I.V.; Vikhrova, A.S.; Utyashev, I.A.; Kharkevich, G.Y.; Petenko, N.N.; Shubina, I.Z.; Demidov, L.V.

Авторы: Orlova Kristina V., Ledin Evgeniy V., Zhukova Natalia V., Orlova Rashida V., Karabina Elena V., Volkonskiy Mikhail V., Stroyakovskiy Daniil L., Yurchenkov Aleksandr N., Protsenko Svetlana A., Novik Alexey V., Vorotilina Ludmila V., Moiseenko Fedor V., Chang Victor L., Kazmin Aleksandr I., Tkachenko Svetlana A., Gamaunov Sergey V., Naskhletashvili David R., Samoylenko Igor V., Vikhrova Anastasia S., Utyashev Igor A., Kharkevich Galina Yu, Petenko Natalia N., Shubina Irina Zh, Demidov Lev V.
Журнал: Cancers
Том: 13
Номер: 11
Год издания: 2021
Издательство: MDPI
Местоположение издательства: Basel, Switzerland
Первая страница: 2529
DOI: 10.3390/cancers13112529
Аннотация: Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival rates. However, real-world data on treatment patterns and clinical outcomes for patients with advanced BRAF V600 mutant melanoma are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 patients with advanced BRAF V600 mutant melanoma, who received TT in a real-world setting and were not involved in clinical trials. The data were collected from twelve medical centers in Russia. The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy; 9.4 months and 16.1 months, respectively, for the combined second-line therapy; and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile.
Добавил в систему: Самойленко Игорь Вячеславович

	ИСТИНА	Войти в систему Регистрация
	ИПМех РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИПМех РАН

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)статья